Epigenetic Reprogramming of Human Hepatoma Cells: A Low-Cost Option for Drug Metabolism Assessment
Open Access
- 1 January 2018
- journal article
- letter
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 5 (3) , 454-457.e1
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Long-term culture and expansion of primary human hepatocytesNature Biotechnology, 2015
- Epigenetic reprogramming modulates malignant properties of human liver cancerHepatology, 2014
- Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor DecitabineOncotarget, 2013
- Vascularized and functional human liver from an iPSC-derived organ bud transplantNature, 2013
- Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor CellsCancer Cell, 2012
- Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivoInternational Journal of Cancer, 2011
- Highly Efficient Generation of Human Hepatocyte–Like Cells From Induced Pluripotent Stem CellsHepatology, 2009
- The Epigenomics of CancerCell, 2007
- Idiosyncratic drug hepatotoxicityNature Reviews Drug Discovery, 2005
- Infection of a human hepatoma cell line by hepatitis B virusProceedings of the National Academy of Sciences, 2002